Tag: George Tsafalas

May 11, 2020

Codebase Ventures Inc. Updates Advancement on Hydroxychloroquine Strategy

Company Has Secured Rights to Innovative Transdermal Delivery for Hydroxychloroquine Which Is Anticipated to Reduce Side Effects and Improve Outcomes
April 23, 2020

Codebase Investment Adds Oral Mucosal Patent Filing, Expanding Transdermal Treatments

New US Provisional Patent Filing for Novel Oral Drug Delivery of Chloroquine and/or Hydroxychloroquine Complements Transdermal Patch for drug used...
April 20, 2020

Codebase Ventures: Hydroxychloroquine Treatment for COVID-19 Benefits Sought in Global Research Effort to Establish Efficacy

Codebase Ventures (CSE:CODE) builds upon its announcement of April 16th regarding its binding LOI to invest in an arms-length private company...
April 16, 2020

Codebase Ventures Inc. Announces $1.5 Million Financing and First Closing of Financing

Codebase Ventures Inc. (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is undertaking a non-brokered private placement of up to $1,500,000.
April 16, 2020

Codebase to Invest in Company Developing Hydroxychloroquine Transdermal Treatment

Codebase Ventures (CSE:CODE) has finalized a definitive agreement as of April 15th, 2020, securing the rights to an innovative drug...
March 5, 2020

Code Ventures Inc. Extends Expiry Date of Certain Warrants

Codebase Ventures Inc. announces extended expiry date of an aggregate of 9,066,666 previously issued warrants for an additional 2 years.
February 26, 2020

Codebase Ventures Inc. Closes Non-Brokered Private Placement

Codebase Ventures Inc. announces it has completed the final tranche of its non-brokered private placement.